Identification of novel PARP-1 inhibitors by structure-based virtual screening

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5790-4. doi: 10.1016/j.bmcl.2013.09.007. Epub 2013 Sep 10.

Abstract

Poly(ADP-ribose)polymerase-1 (PARP-1) is an abundant and ubiquitous chromatin-bound nuclear protein. PARP-1, a DNA repair enzyme, has been in the limelight as a chemotherapeutic target. In this study, we demonstrated the successful use of structure-based virtual screening to identify inhibitors of PARP-1 from Otava databases comprised of nearly 260,000 compounds. Five novel inhibitors belonging to thienopyrimidinone, isoquinolinoquinazolinone, pyrroloquinazolinone, and cyclopentenothienopyrimidinone scaffolds revealed inhibitory potencies with IC50 values ranged from 9.57μM to 0.72μM. Structural features relevant to the activity of these novel compounds within the active site of PARP-1 are discussed in detail and will guide future SAR investigation on these scaffolds.

Keywords: Cyclopentenothienopyrimidinone; Docking; Isoquinolinoquinazolinone; PARP-1; Thienopyrimidinone; Virtual screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Catalytic Domain
  • Drug Design
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Molecular Docking Simulation
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Poly(ADP-ribose) Polymerases / chemistry
  • Poly(ADP-ribose) Polymerases / metabolism
  • Pyrimidines / chemistry*
  • Pyrimidines / pharmacology
  • Quinazolinones / chemistry*
  • Quinazolinones / pharmacology
  • Structure-Activity Relationship

Substances

  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Pyrimidines
  • Quinazolinones
  • thienopyrimidine
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerases